Intra-Cellular Therapies, Inc.

NASDAQ:ITCI

131.87 (USD) • At close April 2, 2025
Bedrijfsnaam Intra-Cellular Therapies, Inc.
Symbool ITCI
Munteenheid USD
Prijs 131.87
Beurswaarde 14,047,056,140
Dividendpercentage 0%
52-weken bereik 64.09 - 131.98
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Dr. Sharon Mates Ph.D.
Website https://www.intracellulartherapies.com

An error occurred while fetching data.

Over Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which

Vergelijkbare Aandelen

Azenta, Inc. logo

Azenta, Inc.

AZTA

27.71 USD

Ionis Pharmaceuticals, Inc. logo

Ionis Pharmaceuticals, Inc.

IONS

32.75 USD

10x Genomics, Inc. logo

10x Genomics, Inc.

TXG

8.63 USD

Option Care Health, Inc. logo

Option Care Health, Inc.

OPCH

31.7 USD

HealthEquity, Inc. logo

HealthEquity, Inc.

HQY

91.33 USD

Integra LifeSciences Holdings Corporation logo

Integra LifeSciences Holdings Corporation

IART

12.89 USD

Exelixis, Inc. logo

Exelixis, Inc.

EXEL

36.5 USD

Omnicell, Inc. logo

Omnicell, Inc.

OMCL

25.39 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)